Gujarat FDCA receives Rs. 32 crore from state govt to expand Surat drug testing lab

Mumbai:  The Gujarat Food and Drug Control Administration (FDCA) has received Rs. 32 crore to expand its drug testing laboratory in Surat, as part of a larger state initiative to strengthen pharmaceutical quality control infrastructure.

Dr. Hemant G. Koshia, Commissioner of FDCA, confirmed that the 2,500-square-meter Surat lab, which was completed over three years, is now set to enter the equipment procurement phase. “The task of procurement of equipment and consumables for the Surat lab has been assigned to the Gujarat Medical Services Corporation Limited (GMSCL),” said Dr. Koshia.

GMSCL is an autonomous body incorporated under the Companies Act for systematic procurement, inventory management, management information system and to infuse professional management with establishment, development and strengthening the use of information technology in medical store organization.

He also stated that GMSCL will initiate the tendering process through the Government e-Marketplace (GeM). “GMSCL will begin the tendering process for equipping the Surat and Rajkot labs. This marks a key step toward enhancing the state’s capacity for pharmaceutical testing,” he added.

In addition to the Surat facility, a new drug testing lab is also being set up in Rajkot. Equipment procurement for the Rajkot lab will also be managed by GMSCL. These developments are part of a broader effort to expand Gujarat’s drug testing network, which will include a new major facility planned in either Ahmedabad or Gandhinagar.

“District collectors and revenue departments have been approached to identify and allocate suitable land. The state government has already earmarked Rs. 12.33 crore for the proposed laboratory in this fiscal year,” said Dr Koshia.

He emphasized that these projects are aimed at building a modern and comprehensive drug testing ecosystem in Gujarat, aligned with both national and international standards. “These investments reflect our commitment to strengthening pharmaceutical regulatory infrastructure and ensuring drug quality for public health,” he noted.

The expanded network also includes the upgraded microbiological drug testing lab in Vadodara, which became operational in May 2023. Built at a cost of Rs. 48 crore, the Vadodara lab spans 16,000 square meters and is equipped with class 100 cleanrooms and advanced airlock systems. Dr Koshia highlighted that the Vadodara facility is the largest of its kind in Asia, offering advanced capabilities for microbiological and pharmaceutical testing.

With ongoing developments in Surat, Rajkot, Vadodara, and the proposed Ahmedabad/Gandhinagar facility, the FDCA is working toward establishing Gujarat as a national hub for drug quality testing and regulation.

Related Posts

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

New Delhi: The Centre has disclosed a significant enforcement action against hospitals found violating the guidelines of the Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), with 2,359 hospitals de-empanelled, 1,200…

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry